Advertisement

Topics

Sobi Realigns Focus On Late-Stage Hematology & Immunology Assets

00:40 EDT 14 Jun 2019 | SCRIP

Swedish specialty pharma and rare diseases company seeks to sustain recent rapid revenues growth with increased R&D focus and investments...

      

Related Stories

 

Original Article: Sobi Realigns Focus On Late-Stage Hematology & Immunology Assets

NEXT ARTICLE

More From BioPortfolio on "Sobi Realigns Focus On Late-Stage Hematology & Immunology Assets"

Advertisement
Quick Search
Advertisement
Advertisement